The Journal of the National Cancer Institute (JNCI) reported new findings from the (GEMCAD)-1402 trial, which investigated the addition of aflibercept in the treatment of locally advanced rectal adenocarcinoma.
The Journal of the National Cancer Institute (JNCI) reported new findings from the (GEMCAD)-1402 trial, which investigated the addition of aflibercept in the treatment of locally advanced rectal adenocarcinoma.
Comments are closed.